Tufts OpenCourseware
Search
Author: Ronald Lechan, MD,PhD
Color Key
Important key words or phrases.
Important concepts or main ideas.

1. Objectives

  • To learn the classification of pituitary adenomas and appreciate that non-secreting adenomas and prolactinomas are the most common pituitary adenomas
  • To learn the mechanisms underlying the development of pituitary adenomas
  • To appreciate that not all hyperprolactinemia is due to a prolactinoma and to learn the differential diagnosis of hyperprolactinemia
  • To learn the pathogenesis and clinical manifestations of prolactinoma
  • To learn the pathogenesis and clinical manifestations of somatotroph adenoma (Acromegaly)
  • To learn the diagnostic algorithm of hypercortisolism.
  • To learn the pathogenesis and clinical manifestations of corticotroph adenoma (Cushing's disease)
  • To learn the pathogenesis and clinical manifestations of non-secreting pituitary adenoma

2. Introduction

Pituitary hypersecretion may occur for several reasons. It may occur physiologically, for example when LH and FSH rise during menopause due to loss of feedback inhibition by gonadal steroids, or when ACTH rises during stress; as a result of hyperplasia of one or more cell types in the anterior pituitary due to the hypersecretion of hypothalamic releasing factors from tumors in the hypothalamus (harmatomas, gangliocytomas) or in the periphery (carcinoids, islet cell tumors), or arise directly from pituitary adenomas. The following will focus exclusively on pituitary adenomas, the most common cause for pathologic hypersecretion of the anterior pituitary.

Pituitary adenomas arise from anterior pituitary cells and therefore, are almost always located in the sella turcica, the bony recess of the sphenoid bone in the middle cranial fossa. They comprise approximately 10% of all intracranial neoplasms. Adenomas that are less than 1 cm in diameter are commonly referred to as microadenomas, whereas adenomas that are 1 cm or more are commonly referred to as macroadenomas. Macroadenomas and often microadenomas can be visualized by magnetic resonance imaging (MRI) as shown in Figure 1. Radiologic imaging techniques cannot identify the type of pituitary adenoma. A subgroup of macroadenomas is classified as invasive due to their massive size and invasion of local structures. Pituitary adenomas are common disorders as up to 27% of individuals at autopsy are found to have one. It can be assumed, therefore, that the majority of pituitary adenomas go unrecognized during life and only those that result in endocrine syndromes as a result of their hypersecretion or cause problems as a result of local growth and compression of adjacent structures or hypopituitarism, come to medical attention.

Figure 1. Macroadenomas and often microadenomas can be visualized by magnetic resonance imaging (MRI)
Figure 1. Macroadenomas and often microadenomas can be visualized by magnetic resonance imaging (MRI)

3. Pathogenesis of Pituitary Neoplasia

Virtually all pituitary adenomas are clonal, i.e. they arise from a single cell. This indicates that the cause for adenoma formation arises from a genetic alteration intrinsic to the anterior pituitary. This alteration may occur as a result of single point mutations that result in excess gene expression (activating mutations) or disruption of genes that are involved in the suppression of cell proliferation (inactivating mutations). For example, in approximately 30 - 40% of Caucasians with somatotroph adenomas (acromegaly), the pathogenesis is believed to be secondary to an activating mutation involving the stimulatory G proteins (Gs). Missense mutations replacing residue 201 (Arg to Cys or His) or 227 (Gln to Arg or Leu) result in ligand-independent constitutive activation of the GHRH receptor and thereby cAMP, which may contribute to the growth and hypersecretory state of these adenomas. Inactivating mutations may be responsible for the increased incidence of pituitary adenomas in the multiple endocrine neoplasia type I syndrome (MEN-I), an autosomal dominant genetic disorder due to a mutation of the menin gene on chromosome 11 that is believed to be a tumor suppresser gene. Excess secretion of basic fibroblast growth factor (FGF-2) and a novel pituitary tumor transforming gene product, PTTG, are also thought to have an early role in pituitary cell transformation. The majority of pituitary adenomas are benign. Rarely, malignant transformation of a pituitary adenoma occurs, which may be associated with metastasis both within and outside of the CNS, likely secondary to a second mutation that may include ras and p53 mutations as late events.

4. Etiology of Pituitary Adenomas

Pituitary adenomas are probably best classified by their hypersecretory product. It must be understood, however, that some tumors secrete more than one pituitary hormone (plurihormonal adenomas). Often pituitary adenomas may synthesize one or more of the classic anterior pituitary hormones. Some pituitary adenomas are incapable of secretion or may secrete the alpha- or beta subunits of the glycoprotein hormones (LH, FSH, TSH) that might otherwise go unnoticed due to their biologic inactivity. Table 1 lists the most common types of pituitary adenomas, their most abundant secretory products and their relative frequency.

Table 1. Classification of Pituitary Adenomas
Tumor Type Secretory Product(s) Relative Frequency (%)
Prolactinoma (Lactotroph Adenoma) Prolactin 50
Somatotroph Adenoma Growth Hormone/Prolactin 10
Corticotroph Adenoma ACTH 5
Thyrotroph Adenoma TSH 1
Nonsecreting Adenoma α alpha -subunit 34

4.1. Lactotroph Adenoma (Prolactinoma)

The prolactinoma is the most common pituitary adenoma. In women, the majority of prolactinomas present as microadenomas whereas in men, the majority present as macroadenomas. This does not necessarily indicate that microadenomas become macroadenomas. In fact, several studies have demonstrated that in women, microadenomas remain microadenomas, even when followed for as long as 15 years. Thus, prolactinomas comprise part of a group that may have different biologic behaviors. Symptoms associated with hyperprolactinemia are listed in Table 2. Amenorrhea and impotence are due to the effect of prolactin to inhibit GnRH secretion with the subsequent reduction in LH/FSH secretion, as well as interference with the actions of LH/FSH at the gonads. The result is a fall in estrogen or testosterone levels. Prolactin may also stimulate androgen secretion from the gonads and adrenal gland, resulting in hirsutism. Because microadenomas are more commonly found in women, symptoms due to compression of local structures are generally found in men.

Table 2. Clinical Manifestations of Hyperprolactinemia
Women Men
Galactorrhea (found in about 30 - 80% of women) Galactorrhea (found in less than < 10% of men)
Amenorrhea Impotence
Infertility Hypogonadism
Hirsutism Visual Field Abnormalities
Extraoccular Muscle Palsies
Headaches

Unless the plasma prolactin level is greater than 250 ng/ml (Normal < 20 ng/ml), other etiologies should be considered as the cause for the hyperprolactinemia. These are listed in Table 3.

Table 3. Etiologies of Hyperprolactinemia (adapted from M.E. Molitch, Endocrinology and Metabolism Clinics of North America, 28, 143-169, 1999)
Pituitary Disease Hypothalamic Disease Medication
Prolactinoma
Acromegaly
Nonsecreting Adenoma
Empty Sella Syndrome
Lymphocytic Hypophysitis
Craniopharyngioma
Meningioma
Dysgerminoma
Histiocytosis
Sarcoidosis
Stalk Section
Phenothiazines
Haloperidol Reserpine
XMAO Inhibitors
Tricyclic Antidepressants
Methyldopa
Metoclopramide
Cocaine
Verapimil
Fluoxetine
Neurogenic Other
Herpes Zoster
Chest wall lesions
Spinal Cord Lesions
Breast Stimulation
Pregnancy
Hypothyroidism
Renal Failure

In the normal pituitary gland, prolactin release is primarily under inhibitory regulation by dopamine (Figure 2). Thus, anything that disconnects the hypothalamus from the anterior pituitary or disrupts blood flow from the hypothalamus to the anterior pituitary will cause hyperprolactinemia. Decreased metabolism of prolactin, as may occur in renal failure, or medications that antagonize the dopamine D2 receptor commonly used for psychiatric disorders, will also cause hyperprolactinemia. Finally, a number of peptides intrinsic to the hypothalamus including TRH (thyrotropin-releasing hormone) and VIP (vasoactive intestinal polypeptide) act as prolactin-releasing factors. Stimuli that increase these peptides such as hypothyroidism or breast stimulation, respectively, will also cause the release of prolactin. Since the majority of women with prolactinomas have prolactin levels below 150 ng/ml, distinguishing a prolactinoma from other causes for hyperprolactinemia is particularly important.

Figure 2. Physiology of Prolactin Secretion
Figure 2 - Inhibitory regulation by dopamine

Prolactin is primarily under tonic inhibitory control by the hypothalamus through the release of dopamine (DA). Several prolactin-releasing factors (PRFs) have been identified in the hypothalamus that may play a role under certain conditions such as suckling or stress. In the case of suckling (or breast stimulation), tonic inhibition of prolactin secretion is overridden by neurogenetic signals from the breast through a multisynaptic pathway that stimulates PRF and inhibits dopamine. Estrogen also induces hyperplasia and hypertrophy of prolactin cells and increases prolactin secretion.

Treatment of patients with prolactinomas depends upon the size of the adenoma and symptoms. If the adenoma is small and symptoms are minimal, observation may be all that is necessary since the majority of these adenomas will not enlarge. Some adenomas that require therapy respond medically to the dopamine agonists, bromocriptine or cabergoline. By stimulating dopamine D2 receptors on the adenoma, these drugs cause a reduction in tumor size and inhibit prolactin synthesis and secretion. Morphologically, treated tumors show involution of rough endoplasmic reticulum, decreased cytoplasmic volume, and reduced secretory vesicles. Most adenomas will regrow, however, if therapy is stopped. If resistant to medical therapy, transsphenoidal surgery is performed. Surgical success rates are high for microadenomas (>70%) but postoperative recurrence may be as high as 50% over 5 years. Macroadenomas are more difficult to cure by surgery with a success rate of only ~30%. Radiotherapy is not very effective and is only used as a last resort.

4.2. Somatotroph (GH) Adenoma

Hypersecretion of growth hormone (GH) results in gigantism in children and adolescents before closure of the epiphysis, and acromegaly in adults. GH is a 191 amino acid protein which is normally secreted in a pulsatile fashion, every 2-4 hours. There is also a diurnal variation to GH secretion such that more GH is secreted during the night than during the day. GH secretion is under hypothalamic control, as shown in Figure 3. GH secretion is under the regulation of two hypothalamic peptides, GH releasing hormone (GHRH), which stimulates GH secretion and somatostatin, which inhibits GH secretion. These two peptides are likely responsible for the pulsatile secretion of GH.

Figure 3. Physiology of GH Secretion
GH secretion is under hypothalamic control
GH secretion is under hypothalamic control
GH is primarily under the regulation of two opposing regulatory peptides, GHRH andsomatostatin. GHRH stimulates GH transcription and secretion by activating cAMP, whereas somatostatin inhibits GH secretion by reducing cAMP. GH stimulates IGF-1, and IGF-1 then exerts feedback effects on the pituitary toinhibit GHRH secretion. GH also exerts short feedback effects directly on somatostatin neurons to increase its secretion and on GHRH neurons to inhibit GHRH. Reciprocal inhibitory connections between GHRH and somatostatin neurons may further contribute to the regulation of GH secretion.

It is also important to recognize that the actions of GH are only partly due to direct effects of this protein. Many of the actions of GH are mediated by insulin-like growth factor-1 (IGF-1), formally called somatomedin C, which is secreted primarily by the liver (but also other tissues) under the influence of GH. The actions of GH and IGF-1 are listed in Table 4. Because of the pulsatile nature of GH and its short half-life in the circulation (20-25 minutes) compared to the constant levels of IGF-1, measurement of random GH levels are generally not helpful in the diagnosis of acromegaly. Indeed, nighttime GH levels at the peak of a GH spike can be well within the range of an individual with acromegaly. Conversely, normal GH levels may also be found in individuals with acromegaly but these individuals lose the normal pulsatile rhythm of GH.

Table 4. Physiological Effects of GH and IGF-1

GH IGF-1
Insulin Resistance Enhanced Protein Synthesis
Lipolysis Stimulation of Skeletal Growth
Stimulate IGF-1 Cell Proliferation
Immunomodulation

GH hypersecretion is almost always due to a pituitary adenoma. Rarely, excess GH secretion may result from hyperplasia of anterior pituitary somatotrophs as a result of ectopic secretion of GHRH (from carcinoid tumors or other neuroendocrine tumors, small cell lung cancer) or due to the genetic disorder, McCune-Albright syndrome (characterized by polyostotic fibrous dysplasia, pigmented skin patches, endocrine abnormalities).

Acromegaly is largely a disorder of middle age, with a peak incidence between 40 and 50 years. Similar to other pituitary adenomas, the manifestations of acromegaly are due to the metabolic consequences of GH hypersecretion and direct mass effects. Acromegaly leads to profound physical deformity due to skeletal overgrowth (bone and cartilage) and fibroblast proliferation under the influence of IGF-1. This is particularly manifest in the facial bones, where there may be enlargement of the mandible, resulting in protrusion of the jaw (prognathism), dental malocclusion, and often increased spacing between the teeth. The facial features are thickened, coarsened, or swollen, making skin creases very pronounced, partly due to sodium and water retention and increased glycosaminoglycan accumulation in the skin. The lips and tongue become very large. Increased cartilaginous growth contributes to the very prominent nose. Enlargement of the hands and feet result in the common complaint that ring, glove and shoe size increase. Arthralgias are particularly common (75%) due to cartilaginous overgrowth in the joints resulting in misalignment and destabilization of the joints and ultimately joint destruction. Other manifestations of acromegaly are listed in Table 5. If untreated, acromegaly is associated with a 2 to 3-fold increased mortality due to cardiovascular disease (hypertension, cardiomyopathy, arrhythmias, stroke), cancer (adenocarcinoma of the colon), and respiratory impairment. It is important to make the diagnosis of acromegaly early to prevent many of the devastating complications including premature mortality. Many of the manifestations of soft tissue overgrowth can be reversed, at least in part, by treatment.

Table 5. Manifestation of Acromegaly (adapted from A.G. Harris, Acromegaly and Its Management, Lippincott-Raven, 1996)
General Cardiovascular Gastrointestinal
Soft Tissue Swelling Hypertension Colonic Polyps
Acral Enlargement Cardiac Enlargement Enlarged colon
Musculoskeletal Respiratory Neurologic
Arthralgia Tongue Enlargement Paresthesias
Prognathism Sleep Apnea Carpal Tunnel Syndrome
Somnolence
Cutaneous Psychological Metabolic
Increased Sweating Depression Hyperlipidemia
Acne Decreased Vitality Hyperlipidemia
Skin Tags Hypercalcuria

The diagnosis of acromegaly is confirmed by demonstrating that GH secretion cannot be suppressed below 1 ng/ml with a glucose load (oral glucose tolerance test, OGTT). One could also establish the diagnosis by frequent sampling of GH and demonstrating the absence of normal pulsatile GH secretion, but this is time consuming and costly and not readily available in clinical practice. Measurement of a single IGF-1 level may suggest the diagnosis of GH excess but IGF-1 can be elevated in physiologic conditions such as puberty or pregnancy and falsely low in liver disease, renal disease, malnutrition or with exogenous estrogen administration.

The majority (over 70%) of patients with acromegaly have macroadenomas, due to the insidious nature of the disease and delay in diagnosis. The goal of therapy is to control GH hypersecretion and reduce tumor volume. Transsphenoidal surgery is the treatment of choice for most patients. Following surgery, GH assessment should be done with measurement of IGF-1 as well as repeat OGTT. Microadenomas can be removed by transsphenoidal surgery with an approximately 80% success rate. Less than 50% of individuals with macroadenomas achieve a surgical cure. Preoperative GH levels are inversely related to surgical success. Radiation therapy is only partly successful in reducing GH hypersecretion to normal, although preliminary data using gamma knife therapy has suggested an approximately 60% cure over 4 years. Several medical treatments (shown in Table 6) have recently become available to control the GH hypersecretion and/or the effects of GH in the periphery. These medications can be used as primary therapy in individuals who have microadenomas to control GH hypersecretion, but generally used as secondary therapy following transsphenoidal surgery, if GH hypersecretion persists.

Table 6. Medical Therapy for Acromegaly
Drug Mechanism of Action
Bromocriptine
Cabergoline
Pergolide
Ergot alkaloids that bind to the dopamine D2 receptor. Mechanism unknown, presumably a paradoxical inhibition of dopamine on GH secretion from the adenoma.
Octreotide
Octreotide-LAR
Lanreotide
Somatostatin analogs; inhibits GH secretion by binding to somatostatin 2 and 5 receptors.
Pegvisomant GH receptor antagonist; prevents dimerization of the GH receptor, thereby preventing the action of GH which results in reduction of IGF-1 level

4.3. Corticotroph (ACTH) Adenoma

Excess secretion of ACTH results in Cushing's syndrome (Cushing's disease if due to a pituitary adenoma) as a result of excessive stimulation of the adrenal cortex and hypersecretion of cortisol. ACTH is normally under negative feedback inhibition by circulating levels of cortisol as shown in Figure 4.

Figure 4. Physiology of ACTH Secretion
ACTH is normally under negative feedback inhibition by circulating levels of cortisol
CRH stimulates ACTH secretion by activating protein kinase A after binding to CRH receptors on the corticotrophes. Vasopressin is a weak ACTH-releasing factor but acts together with CRH to potentiate ACTH secretion. This synergistic action may be important during times of stress. ACTH stimulates cortisol secretion from the adrenal cortex. Cortisol then feeds back on corticotrophes in the pituitary to inhibit the biosynthesis and secretion of proopiomelanocortin (POMC), the precursor of ACTH, and inhibits the biosynthesis and secretion of CRH and vasopressin. Leptin, a fat-derived protein, and cytokines may also influence CRH secretion.

ACTH-secreting pituitary adenomas are partially autonomous such that they retain feedback inhibition by cortisol but at a higher set point. Hence, ACTH and cortisol can be suppressed in individuals with ACTH-secreting pituitary adenomas if given a large enough dose of glucocorticoids.

Classically, a semi-synthetic steroid such as dexamethasone was used to assess suppressibility because it does not interfere with radioimmunoassays that measure cortisol.

By administering graded doses of Dexamethasone (Liddle test) to individuals suspected of having Cushing's syndrome and measuring urinary free cortisol levels, it is possible in most instances to separate out which individuals have adrenal adenomas, ACTH-secreting adenomas, or secrete ACTH ectopically (eg. oat cell carcinoma, medullary thyroid carcinoma, islet cell tumors, pheochromocytoma), from individuals who are simply obese. Normal (or obese) individuals will suppress urinary free cortisol levels to less than 20 µg/dl with low dose Dexamethasone (0.5 mg every 6 h for 2 days), whereas in general, individuals with Cushing's for any reason will not. Furthermore, individuals with an ACTH-secreting pituitary adenoma will suppress urinary free cortisol to >70-80% of baseline with high dose Dexamethasone (2.0 mg every 6 h for 2 days), whereas this does not generally occur with the ectopic ACTH syndrome or adrenal adenomas. Adrenal adenomas can be separated from ectopic ACTH syndnrome by measuring a plasma ACTH level. This tends to be very low in adrenal adenomas due to suppression of anterior pituitary corticotrops by autonomous secretion of cortisol from the adrenal adenoma, and very high in the ectopic ACTH syndrome.

Unfortunately, it is now realized that there can be a considerable degree of overlap between ACTH-producing adenomas, and ACTH secreted ectopically from carcinoid tumors, making the distinction difficult between these two entities using the high dose Dexamethasone suppression test. Nevertheless, the Dexamethasone suppression test is still valuable in differentiating normal or obese individuals from those with Cushing's. A simplified test that involves the administration of only 1 mg of Dexamethasone at 11PM and the measurement of an 8AM serum cortisol the following morning (overnight Dexamethasone suppression test) has largely replaced the Liddle test. In most instances, normal individuals will suppress serum cortisol to <5 µg/dl, and often to <1.8 µg/dl due to the exquisite sensitivity of normal anterior pituitary corticotrophs to Dexamethasone.

Alternatively, measurement of a late night plasma or salivary cortisol can be used to distinguish individuals with Cushing's from normal individuals. This is based on the normal physiologic diurnal variation of cortisol, which peaks at around 8 AM and has its nadir at around midnight. Thus, a normally suppressed cortisol at midnight excludes the diagnosis of Cushing's. This test is particularly useful to distinguish individuals that may have clinical and biochemical features that suggest Cushing's disease but do not actually have Cushing's disease. These individuals are said to have pseudo-Cushing's. Pseudo-Cushing's can be caused by excessive alcohol intake, depression, severe obesity, and severe illness and may be due to alterations in the set point for feedback inhibition of CRH or ACTH by cortisol. The normal circadian rhythm of cortisol is preserved in pseudo-Cushing's, which can be helpful to distinguish these individuals from true Cushing's by measuring salivary cortisol levels at 8 AM and 11 PM. The abnormal Dexamethasone suppression reverts to normal upon correction of the precipitating cause.

The following schema can be used to establish the diagnosis of Cushing's and to identify the major subtypes:

Figure 5. Diagnostic algorithm for Cushing's syndrome
Figure 5. Diagnostic algorithm for Cushing's syndrome

Individuals with Cushing's disease may have a variety of clinical manifestations, depending upon the severity and duration of the disorder before diagnosis. A number of characteristic features are listed in Table 7.

Table 7. Features of Cushing's Disease
General Cardiovascular Psychiatric
Central Obesity Hypertension Depression
Cutaneous Musculoskeletal Metabolic
Facial Plethora Proximal Myopathy Glucose Intolerance
Hirsutism Osteopenia Diabetes Mellitus
Wide Striae (>1cm) Osteoporosis Hypokalemia
Bruising Back Pain Hypercalcuria
Supraclavicular Fullness Muscle Wasting

Treatment of Cushing's disease is primarily surgical, removal of the pituitary adenoma by transsphenoidal surgery. For individuals not cured by transsphenoidal surgery, conventional radiation or gamma knife therapy, bilateral adrenalectomy and/or medical therapy (shown in Table 8) are options.

Table 8. Medical Therapy for Cushing's Disease
Drug Mechanism of Action
Ketoconazole Antifungal agent; blocks cholesterol side-chain cleavage to reduce cortisol. May have independent inhibitory actions directly on ACTH secretion.
Metyrapone Inhibits 11β -hydroxylase to reduce cortisol. May also cause hypertension and hypokalemia due to increase in 11-deoxycorticosterone, and hirsutism due to increased androgens.
Aminoglutethimide Often used together with metyrapone to reduce side effects. Inhibits cholesterol side-chain cleavage and 11β /18-hydroxylation. May cause hypothyroidism by interfering with iodine incorporation into thyroid hormone.
Mitotane Destructive to adrenal cortex. Frequent adverse reactions. May cause hypercholesterolemia due to activation of HMG coenzyme reductase.
Mifepristone Glucocorticoid antagonist. Not approved in U.S.

4.4. Thyrotroph (TSH) Adenomas

Thyrotroph adenomas are very rare pituitary adenomas. The vast majority of these tumors are macroadenomas and, therefore, may be associated with mass effects. The clinical presentation is that of thyrotoxicosis due to excessive TSH secretion. A goiter occurs in greater than 90% of cases. Graves' disease is often misdiagnosed in these patients, but the inappropriate increase in TSH for the elevated levels of thyroid hormones (T4 and T3) and the absence of ophthalmopathy, allow differentiation between these two disorders. Resistance to thyroid hormone due to mutations of the thyroid hormone receptors may also result in seemingly inappropriately elevated TSH levels for the circulating levels of thyroid hormones, but can be differentiated from thyrotroph adenomas by the high serum, α-subunit to TSH molar ratio found with thyrotroph adenomas (alpha-subunit [ng/ml] / TSH [mIU/ml] over 1 in TSH adenomas).

Transsphenoidal surgery is the primary therapy for thyrotroph adenomas, but complete removal is difficult because of the large size of these tumors. Radiation therapy and/or medical therapy with octreotide are used for individuals with persistent disease. Octreotide is very effective in reducing TSH secretion to normal and reversing thyrotoxicosis, but is not very effective in shrinking the tumor.

4.5. Non-Secreting Adenomas

The majority of nonsecreting adenomas (90%) are actually glycoprotein hormone-producing adenomas, and contain various subunits of the glycoprotein hormones including α-subunit, β-LH and β-FSH. Some of these tumors actually do secrete FSH or α-subunits, but because these subunits are clinically nonfunctional, syndromes such as described above for acromegaly or Cushing's disease, are not usually observed. A small number of men with hypersecretion of intact FSH have been described and had testicular enlargement. As a result, most of these tumors come to attention because of mass effects and/or hypopituitarism. Hyperprolactinemia is usually present due to stalk compression by the large mass and needs to be differentiated from a prolactinoma.

Treatment depends upon the size of the adenoma. Small adenomas do not necessarily require treatment if they do not compress local structures or cause hypopituitarism. Periodic MR images to assess the rate of growth may be all that is necessary. Large tumors are treated by transsphenoidal surgery. Complete resection of the tumor is not necessary. Relief of compressive symptoms is adequate. If hypopituitarism persists following surgery or is caused by the surgery, replacement therapy is given. Occasionally, anterior pituitary function may recover after decompression of the normal residual anterior pituitary.

If the adenoma grows following surgery, radiation therapy can be given. While many of these tumors do have somatostatin receptors, they respond poorly to medical treatment with octreotide and several studies have shown no shrinkage with this drug. Some nonsecreting adenomas also contain dopamine receptors, but their response to dopamine agonists such as bromocriptine and cabergoline are poor. Because nonsecreting adenomas are primarily gonadotroph adenomas and contain GnRH receptors, attempts to shrink the tumor with GnRH analogues (agonists and antagonists) have been tried but also without success.

5. References

  • Freda, PU and Wardlaw SL, Diagnosis and treatment of pituitary tumors, J Clin Encorcinol Metab 84, 3859-3866, 1999.
  • Melmed S, Pathogenesis of pituitary tumors, Endocrinology and MetabolismClinics of North America, 28, 1-12, 1999.
  • Ben-Shlomo A, Melmed S. Acromegaly. Endocrinology and Metabolism Clinics of North America 30, 565-583, 2001
  • Molitch ME. Disorders of prolactin secretion. Endocrinology and Metabolism Clinics of North America 30, 585-610, 2001
  • Raff H, Findling JW. A physiologic approach to diagnosis of the Cushing's syndrome. Ann Intern Med 138, 980-991, 2003